Full-Time

Global Brand Director

Respiratory

Posted on 3/25/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$229.3k - $344k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program + Commission payment eligibility

Expert

Cambridge, UK + 1 more

More locations: Gaithersburg, MD, USA

Requires a minimum of three days per week in the office.

Category
Public Health
Biology & Biotech
Required Skills
Market Research
Branding/Brand Strategy
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a AstraZeneca referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree is required with business degree or scientific expertise as preferred. Master’s degree is desired.
  • A minimum of 10+ years’ experience in healthcare or biopharma industry, with a strong preference for experience in the respiratory therapeutic area, in particular in respiratory disease and/or biologics viral infectious diseases.
  • In-depth understanding of commercial strategy, methodologies and tools (product profiling and positioning, forecasting, pricing & reimbursement, market research techniques, competitive intelligence resources).
  • Thorough ‘hands-on’ knowledge of building TPPs, generating sales forecasts and business cases.
  • Experience of shaping brand strategy whilst the understanding of product profile was incomplete and evolving.
  • Thorough understanding of the drug development process and the need for commercial line of sight throughout.
  • Understanding of future healthcare market challenges including local regulatory DO’s and DON’Ts.
  • Exposure to and track record of effective management of senior decision-making/governance bodies.
  • Proven experience of engaging with and leveraging insights from external customers e.g. KEEs, prescribers, and payors.
Responsibilities
  • Champion the product and LCM program beyond COPD and svLRTD.
  • Launch of COPD, leading some commercial efforts.
  • Developing LCM commercial strategy and future commercial opportunities.
  • Building a robust business case to support a positive commercial investment decision.
  • Represent the commercial LCM voice within the cross functional global product team.
  • Engaging with the head of brand to ensure a flawless and aligned execution of the strategy and incorporation of evidence.
Desired Qualifications
  • Strong understanding and experience of launching medicines in the US health system

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca distinguishes itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-powered tools enhance AstraZeneca's lung cancer detection capabilities, improving early diagnosis.
  • Enhertu shows significant improvement in breast cancer treatment, boosting AstraZeneca's oncology portfolio.
  • Calquence's EU approval for CLL offers a competitive edge in leukemia treatment.

What critics are saying

  • Discontinuation of CAPItello-280 trial impacts AstraZeneca's oncology pipeline and investor confidence.
  • Operational challenges at the new CAR-T facility may delay cell therapy production.
  • AI reliance in lung cancer detection poses risks related to data privacy and accuracy.

What makes AstraZeneca unique

  • AstraZeneca's Open Innovation program accelerates drug discovery through shared compounds and technologies.
  • The A.Catalyst Network fosters global collaboration and innovation in health through 20+ hubs.
  • AstraZeneca's focus on Oncology, Cardiovascular, and Respiratory areas sets it apart in biopharma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

Cision
May 7th, 2025
Enhertu Improved Pcr In Early-Stage Breast Cancer

Enhertu improved pCR in early-stage breast cancer

Bethesda Magazine
May 6th, 2025
AstraZeneca opens cell therapy manufacturing site in Rockville

AstraZeneca announced in February 2024 that it was investing in the Rockville manufacturing facility.

INACTIVE